Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

by Sperone, Paola , Sender, Monica , Hermsen, Ilse , Schteingart, David E , Schade-Brittinger, Carmen , Skogseid, Britt , Berruti, Alfredo , Gelderblom, Hans , Hahner, Stefanie , Kroiss, Matthias , Müller, Hans-Helge , Welin, Staffan , Lacroix, André , Tabarin, Antoine , Haak, Harm , Jarzab, Barbara , Willenberg, Holger S , de la Fouchardière, Christelle , Terzolo, Massimo , Quinkler, Marcus , Fojo, Tito , Allolio, Bruno , Fassnacht, Martin , Baudin, Eric , Leboulleux, Sophie , Arlt, Wiebke , Wilmink, Hanneke , Mantero, Franco , Edgerly, Maureen , Stepan, Vinzenz , Beuschlein, Felix , Kenn, Werner , Torpy, David J , Schlumberger, Martin , Sorbye, Halfdan , Weismann, Dirk , Sundin, Anders

in Adrenal Cortex Neoplasms - drug therapy / Adrenals. Adrenal axis. Renin-angiotensin system (diseases) / Adrenocortical Carcinoma - drug therapy / Adult / Aged / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Biological and medical sciences / Cancer therapies / Chemotherapy / Cisplatin / Cisplatin - administration & dosage / Cytotoxicity / Disease-Free Survival / Doxorubicin / Doxorubicin - administration & dosage / Drug dosages / Endocrinopathies / Etoposide / Etoposide - administration & dosage / Female / General aspects / Hospitals / Humans / Intention to Treat Analysis / Kaplan-Meier Estimate / Male / Malignant tumors / Medical prognosis / Medical sciences / Metastasis / Middle Aged / Mitotane - administration & dosage / Mitotane - adverse effects / Neuroendocrine tumors / Patients / Population / Quality of Life / Response rates / Streptozocin / Streptozocin - administration & dosage / Streptozocin - adverse effects / Survival / Tumors / Young Adult

2012

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

2012

Confirm

Do you wish to request the book?

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

2012

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Sperone, Paola,

Sender, Monica,

Hermsen, Ilse,

Schteingart, David E,

Schade-Brittinger, Carmen,

Skogseid, Britt,

Berruti, Alfredo,

Gelderblom, Hans,

Hahner, Stefanie,

Kroiss, Matthias,

Müller, Hans-Helge,

Welin, Staffan,

Lacroix, André,

Tabarin, Antoine,

Haak, Harm,

Jarzab, Barbara,

Willenberg, Holger S,

de la Fouchardière, Christelle,

Terzolo, Massimo,

Quinkler, Marcus,

Fojo, Tito,

Allolio, Bruno,

Fassnacht, Martin,

Baudin, Eric,

Leboulleux, Sophie,

Arlt, Wiebke,

Wilmink, Hanneke,

Mantero, Franco,

Edgerly, Maureen,

Stepan, Vinzenz,

Beuschlein, Felix,

Kenn, Werner,

Torpy, David J,

Schlumberger, Martin,

Sorbye, Halfdan,

Weismann, Dirk,

Sundin, Anders

2012

Overview

In this large international study of patients with adrenal cancer, a rare, treatment-refractory disease, mitotane plus a combination of etoposide, cisplatin, and doxorubicin had greater antitumor activity than mitotane plus streptozotocin. Adrenocortical carcinoma is a rare cancer (estimated incidence, 0.7 to 2.0 cases per 1 million population per year) 1 , 2 with a poor prognosis; the 5-year survival rate is less than 15% among patients with metastatic disease. 3 – 7 Mitotane is the only drug approved for the treatment of adrenocortical carcinoma and is used both as adjuvant therapy and for advanced disease, 8 – 14 although its efficacy has never been shown in a randomized trial. The experience with other antineoplastic drugs for the treatment of this disease is even more limited. Current treatment strategies for advanced disease are based exclusively on retrospective series . . .

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adrenal Cortex Neoplasms - drug therapy

/ Adrenals. Adrenal axis. Renin-angiotensin system (diseases)

/ Adrenocortical Carcinoma - drug therapy

/ Adult

/ Aged

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use